DUBLIN--(BUSINESS WIRE)--The "Cutaneous T-Cell Lymphoma (CTCL) - Market Insights, Epidemiology and Market Forecasts to 2027" drug pipelines has been added to ResearchAndMarkets.com's offering.
This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of CTCL in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Cutaneous T-Cell Lymphoma (CTCL) from 2016 to 2027 segmented by seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
According to research, the 7MM market of Cutaneous T-Cell Lymphoma (CTCL) was USD 353.5 million in 2016, and is expected to increase at a significant growth during the study period i.e., 2016-2027.
According to research, the incident cases of CTCL in 7 major markets was 8,310 in 2016. Among 7MM United States account for highest incident population of CTCL i.e., 3,207 followed by United Kingdom.
Currently there are six marketed drugs available for the treatment of CTCL including Istodax (Romidepsin), Poteligeo (Mogamulizumab), Valchlor (Mechlorethamine), Uvadex (Methoxsalen), Targretin (Bexarotene) and Zolinza (Vorinostat). Detailed chapters for all of these drugs, along with the promising upcoming therapies including SGX301 (Soligenix Inc), Adcetris (Brentuximab Vedotin), Resminostat (4SC AG) etc have been covered in the report.
Companies Mentioned:
- 4SC AG
- Janssen
- Medivir AB
- Seattle Genetics
- Soligenix
Key Topics Covered:
1. Report Introduction
2. Cutaneous T-Cell Lymphoma Market Overview at a Glance
3. Cutaneous T-Cell Lymphoma Overview
4. Epidemiology of Cutaneous T-Cell Lymphoma
5. Treatment Algorithm
6. Unmet Needs
7. Marketed Drugs
8. Emerging Drugs
9. Emerging Therapies
10. Cutaneous T-Cell Lymphoma: Country-Wise Market Analysis
11. Market Drivers
12. Market Restraints
13. Appendix
14. Report Methodology
15. Capabilities
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/hfj7b4/global_cutaneous?w=4
